Search Results - "Jeandel, P. ‐Y."

Refine Results
  1. 1
  2. 2

    Tranexamic acid as maintenance treatment for non‐histaminergic angioedema: analysis of efficacy and safety in 37 patients by Wintenberger, C., Boccon‐Gibod, I., Launay, D., Fain, O., Kanny, G., Jeandel, P. Y., Martin, L., Gompel, A., Bouillet, L.

    Published in Clinical and experimental immunology (01-10-2014)
    “…Summary Angioedema (AE) is a clinical syndrome characterized by localised swelling lasting several hours. The swelling is often recurring and can be lethal if…”
    Get full text
    Journal Article
  3. 3

    The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression by Baudot, A D, Jeandel, P Y, Mouska, X, Maurer, U, Tartare-Deckert, S, Raynaud, S D, Cassuto, J P, Ticchioni, M, Deckert, M

    Published in Oncogene (17-09-2009)
    “…B-cell chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of mature monoclonal CD5+ B cells. The disease results mainly from a failure of…”
    Get full text
    Journal Article
  4. 4

    Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a by TICCHIONI, M, ESSAFI, M, JEANDEL, P. Y, DAVI, F, CASSUTO, J. P, DECKERT, M, BERNARD, A

    Published in Oncogene (01-11-2007)
    “…B-chronic lymphocytic leukemia (B-CLL) cell is characterized by the accumulation of long-lived CD5+ B lymphocytes, whose survival in vivo is in part dependent…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Successful treatment with rituximab of one patient with CANOMAD neuropathy by Delmont, Emilien, Jeandel, P. Y., Hubert, A. M., Marcq, L., Boucraut, J., Desnuelle, C.

    Published in Journal of neurology (01-04-2010)
    “…We report a successful treatment with rituximab in a patient with CANOMAD neuropathy resistant to previous therapy. The titers of anti-disialosyl antibodies…”
    Get full text
    Journal Article
  7. 7

    The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKC[delta] and proteasome-dependent regulation of Mcl-1 expression by Baudot, A D, Jeandel, P Y, Mouska, X, Maurer, U, Tartare-deckert, S, Raynaud, S D, Cassuto, J P, Ticchioni, M, Deckert, M

    Published in Oncogene (17-09-2009)
    “…B-cell chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of mature monoclonal CD5+ B cells. The disease results mainly from a failure of…”
    Get full text
    Journal Article
  8. 8

    Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment by Gobert, D, Bouillet, L, Armengol, G, Coppo, P, Defendi, F, Du-Thanh, A, Hardy, G, Javaud, N, Jeandel, P-Y, Launay, D, Panayotopoulos, V, Pelletier, F, Boccon-Gibod, I, Fain, O

    Published in La revue de medecine interne (01-12-2020)
    “…Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrum of bradykinin angioedemas. It usually occurs in…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Hereditary angioedema and lupus: A French retrospective study and literature review by Gallais Sérézal, Irène, Bouillet, Laurence, Dhôte, Robin, Gayet, Stéphane, Jeandel, Pierre-Yves, Blanchard-Delaunay, Claire, Martin, Ludovic, Mekinian, Arsène, Fain, Olivier

    Published in Autoimmunity reviews (01-06-2015)
    “…Abstract Hereditary angioedema (HAE) is a rare genetic disorder that is primarily caused by a defect in the C1 inhibitor (C1-INH). The recurrent symptoms are…”
    Get full text
    Journal Article
  11. 11

    Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies by Delmont, Emilien, Jeandel, P. Y., Benaïm, C., Rosenthal, E., Fuzibet, J. G., Desnuelle, C.

    Published in Journal of neurology (01-09-2011)
    “…We report on a series of six patients diagnosed as anti-MAG polyneuropathy treated with rituximab. Nine months after the infusion of rituximab, sensory…”
    Get full text
    Journal Article
  12. 12

    Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term rituximab by Michaud, A, Delmont, E, Jeandel, P-Y, Desnuelle, C

    Published in Revue neurologique (01-12-2011)
    “…Some patients suffering from multifocal motor neuropathy with conduction blocks (MMNCB) are still disabled after treatment with intravenous immunoglobulin…”
    Get full text
    Journal Article
  13. 13

    Efficacy of autologous peripheral blood stem cell transplantation (auto-PBSCT) on the neuropathic manifestations in POEMS syndrome by Gronier, S, Delmont, E, Legros, L, Launay, M, Jeandel, P Y, Fuzibet, J G, Desnuelle, C

    Published in Revue neurologique (01-01-2014)
    “…POEMS syndrome (polyneuropathy, organomegaly, endocrynopathy, M-protein, and skin changes) is a rare multisystem disease associated with plasma cell dyscrasia…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Amélioration d’un cas de neuropathie motrice multifocale avec blocs de conduction sévère, dépendant des immunoglobulines intraveineuses, après adjonction de rituximab au long cours by Michaud, A., Delmont, E., Jeandel, P.-Y., Desnuelle, C.

    Published in Revue neurologique (01-12-2011)
    “…Certains patients atteints de neuropathie motrice multifocale avec blocs de conduction (NMMBC) restent handicapés malgré un traitement par immunoglobulines…”
    Get full text
    Journal Article
  16. 16

    Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women by Billebeau, Aurore, Fain, Olivier, Launay, David, Boccon-Gibod, Isabelle, Bouillet, Laurence, Gobert, Delphine, Plu-Bureau, Geneviève, Gompel, Anne

    Published in Journal of clinical immunology (01-01-2021)
    “…Purpose Most types of hereditary angioedema (HAE) are worsened by endogenous or exogenous estrogens. Conversely, androgens can improve HAE with abnormal…”
    Get full text
    Journal Article
  17. 17

    Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009 by Rosenthal, E, Delaunay, P, Jeandel, P-Y, Haas, H, Pomares-Estran, C, Marty, P

    Published in Médecine et maladies infectieuses (01-10-2009)
    “…Visceral leishmaniasis (VL) causes an estimated 500,000 new cases of disease and more than 50,000 deaths a year. For more than 60 years, pentavalent antimonies…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20